Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MB-102 vs Dual Sugar Testing for Gut Permeability in Crohn's Disease
NCT03962998Phase 1Completed
- Sponsor
- MediBeacon
- Start
- Oct 2019
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of relmapirazin in Crohn's disease (2 arms), sponsored by MediBeacon. Primary endpoint: Mean urine concentration of MB-102 over time at 12 hours. Started Oct 2019; status: completed.
02
Drugs
relmapirazin
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT03962998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03962998.